New endometriosis guidance may help long-suffering patients

By her second period, Leah Chapman could not get out of bed.

She was 12, on vacation with her family in Colorado, and the pain was so severe she stayed inside while everyone else went out. It would take 20 years before someone formally diagnosed her with endometriosis.

As an OB-GYN, I talked with patients about endometriosis almost every day. The conversations were often brief and fragmented, shaped by years of pain that had already been normalized or explained away. Over time, I could feel the public’s understanding of this disease beginning to shift. But the story that stayed with me most did not come from my clinic. It came from Leah, who I met when I stepped more intentionally into women’s health advocacy.

Physicians often cite the average diagnostic delay for endometriosis as four to 11 years. The number appears in studies and policy briefs with clinical neutrality, as if time were a passive variable in a complex system.

But time is not passive in a chronic inflammatory disease. During those years, inflammation progresses. Adhesions form. Ovarian tissue is distorted. Fertility windows narrow. School days are missed. Careers quietly adjust around pain. Financial strain accumulates. Over time, patients begin to reinterpret suffering as ordinary, absorbing the message that this level of pain must simply be part of their biology.

This month, the American College of Obstetricians and Gynecologists released updated clinical guidance on the diagnosis of endometriosis in Obstetrics & Gynecology, replacing prior bulletins and issuing comprehensive recommendations that explicitly include adolescents. The most consequential change is clear. A clinical diagnosis based on symptoms and examination is sufficient to initiate empiric treatment. Surgical confirmation is no longer required before care begins.

This guidance challenges a decades-old model that effectively required patients to endure prolonged uncertainty before meaningful intervention could occur. Laparoscopy had functioned as a diagnostic gatekeeper. While imaging techniques and medical therapies evolved, definitive diagnosis remained tied to surgical visualization. In practice, that threshold often delayed action, reinforcing cycles of normalization and misattribution.

The updated recommendations reflect a growing understanding that endometriosis is a chronic, estrogen-dependent inflammatory condition with heterogeneous presentation. It does not confine itself to the ovaries, nor does it announce itself uniformly. Lesions may involve the uterosacral ligaments, bowel, bladder, abdominal wall, or neural structures. Symptoms vary accordingly.

The recommendations explicitly encourage clinicians to suspect endometriosis in patients presenting with chronic pelvic pain, significant dysmenorrhea (painful periods), deep dyspareunia (pain with deep penetration during intercourse), bowel or bladder pain that fluctuates with the menstrual cycle, or infertility associated with these symptoms. Importantly, these recommendations apply to adolescents as well as adults, acknowledging that the disease often begins years before patients reach subspecialty care.

Although ACOG authored the guideline, endometriosis does not belong solely to gynecology. Its early manifestations frequently surface in other clinics. An adolescent with severe menstrual pain and vomiting may first present to a pediatrician. Cyclical diarrhea or rectal pain may be evaluated by a gastroenterologist and labeled irritable bowel syndrome. Recurrent urinary discomfort without infection may lead to urologic consultation. Chronic low back or sciatic pain that intensifies monthly may be treated as a musculoskeletal problem. Fatigue and anemia may prompt an internal medicine workup. Infertility may bring someone to a reproductive endocrinologist long after years of inflammatory progression.

If endometriosis continues to be conceptualized as a narrowly gynecologic disorder rather than a systemic inflammatory condition with multisystem manifestations, diagnostic delay will persist regardless of updated guidance.

The new recommendations should therefore serve as a cross-specialty inflection point. Menstrual cyclicity is not incidental. When bowel, bladder, musculoskeletal, or neuropathic pain intensifies predictably around menses, the differential must expand. Asking whether symptoms change with the menstrual cycle introduces a temporal framework that can reorient evaluation. That single question may redirect years of fragmented care.

Chapman’s experience illustrates the cost of delay. By the time she received her diagnosis, she had stage 3 disease and a 4-centimeter endometrioma that had initially been misidentified as a hemorrhagic cyst. It grew to 8 centimeters and ruptured, requiring emergency surgery. She and her husband have since undergone four egg retrievals and three embryo transfers. Each IVF cycle at her clinic cost between $20,000 and $30,000, with coverage dependent on state mandates. Since Leah’s job was based in Boston, she received the benefits associated with the state of Massachusetts, which has some of the strongest infertility insurance mandates in the U.S. It requires most insurers to cover diagnosis, treatment, and assisted reproductive technology, including IVF. This is in starck contrast to what is state-regulated where she currently lives in Texas.

Her experience catalyzed advocacy. Chapman founded the Women’s Health Research and Action Center in Houston to address what she recognized as a systems failure, one that extends beyond clinical recognition to research funding, insurance policy, and public awareness. While professional societies refine diagnostic frameworks, patient-led organizations are pressing for structural change so that earlier recognition is matched by access to evidence-based care.

Shortening the diagnostic timeline requires more than an updated algorithm. It requires clinicians across specialties to reconsider how menstrual history is incorporated into evaluation. Symptom patterns often carry more signal than isolated complaints. Dysmenorrhea, dyspareunia, dyschezia (pain with bowel movement), and dysuria (pain with urination) are not required as a full constellation. Lesion location frequently determines which symptom dominates, and some adolescents present only with debilitating menstrual pain that has been normalized within their families for generations.

The absence of every symptom does not exclude the disease, and severe pain should not be dismissed simply because it is common. Endometriosis likely carries genetic contributions, but it also inherits normalization. When a mother missed work monthly and a grandmother described similar cycles, debilitating pain may be framed as expected rather than pathological.

The updated guideline clarifies diagnostic strategy, recommending transvaginal ultrasonography as first-line imaging, reserving MRI for further characterization when needed, and advising against the use of biomarkers for diagnosis. Laparoscopy remains appropriate in selected contexts, but it is no longer a prerequisite to initiating treatment. The barrier to action has been lowered.

What remains is whether practice will follow.

For clinicians evaluating recurrent or chronic pelvic, abdominal, urinary, or musculoskeletal pain in reproductive-age patients, menstrual timing should be considered a meaningful diagnostic variable. Functional disruption should be documented. Longitudinal symptom tracking should be encouraged. When pain is severe, patterned, and persistent, it warrants deliberate evaluation rather than reflex reassurance. The updated guideline lowers the threshold for action. Whether that threshold translates into shorter diagnostic timelines now depends on whether clinicians across specialties incorporate menstrual history as clinically meaningful rather than culturally expected.

Endometriosis does not wait for surgical proof to cause harm. Medicine should not wait for surgical proof to intervene.